Dorzolamide is utilized for managing ocular hypertension. Suppressing carbonic anhydrase activity, this active ingredient reduces aqueous humor production to maintain appropriate clinical pressure levels.
Targeting intra-ocular fluid dynamics, Dorzolamide belongs to the sulfonamide family of carbonic anhydrase inhibitors and primarily reduces the production of aqueous humor. By limiting fluid buildup, it helps to lower intra-ocular pressure, a key factor in glaucoma management. The substance appears as the active component in eye drops such as Cosopt and Trusopt, which are widely prescribed in Singapore. Patients often encounter this molecule when seeking long-term control of pressure-related eye conditions.
Formulated as sterile ophthalmic solutions, the active compound is delivered directly onto the corneal surface. The medication is packaged in single-dose vials or multi-dose bottles equipped with preservative-free options for sensitive users. In Singapore, both branded and generic versions are available, with Cosopt offering a combination of dorzolamide and timolol, while Trusopt provides dorzolamide alone. These formats facilitate convenient self-administration under professional guidance.
Addressing elevated eye pressure, the agent is employed in the treatment of open-angle glaucoma and ocular hypertension. It also assists patients with secondary glaucoma types where fluid drainage is compromised. Individuals with a family history of glaucoma frequently encounter this therapy as part of a preventive strategy. Moreover, eye-care specialists may incorporate it after laser procedures to maintain pressure control.
Modulating enzyme activity in the ciliary body, the medication slows the formation of aqueous humor without altering drainage pathways. This reduction in fluid volume translates into lower pressure on the optic nerve, easing strain that can lead to vision loss. The effect becomes noticeable within days, and steady use supports long-term pressure stability. Because it acts locally in the eye, systemic exposure remains minimal.
Mild eye irritation, temporary blurred vision, and a slight metallic taste are reported by a minority of users. These sensations typically resolve without intervention after continued application.
Rarely, individuals may experience sudden eye pain, severe redness, or swelling that suggests an allergic response. Prompt medical attention is advised if such symptoms emerge.
Pregnant or breastfeeding individuals should avoid exposure unless directed by a clinician. Persons with known sulfonamide hypersensitivity must not use the drops, as cross-reaction can occur.
Alcohol consumption does not directly alter ocular absorption, yet it may increase overall dehydration, potentially affecting eye comfort. Concomitant use of other intra-ocular pressure-lowering agents can enhance the pressure-lowering effect, so reviewing the complete medication list is essential. For precise interaction details, refer to the specific medication's insert.
Storing the eye drops in a cool, dry place away from direct sunlight preserves potency throughout the recommended shelf life. Treatment duration varies; some patients require short-term use after surgery, while others continue indefinitely for chronic management. Formulation differences between Cosopt and Trusopt may influence dosing frequency and storage instructions. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This overview of Dorzolamide provides general educational information and is not medical advice. Individual medicines such as Cosopt and Trusopt differ in strength, formulation, and instructions. The author disclaims any liability for clinical application of the content herein. Patients should review the specific medication labeling and consult a licensed healthcare professional for personalized guidance.
